Facing unprecedented disruption across the value chain, four in ten healthcare CEOs don’t think they will be economically viable a decade from now if they continue on their current path. For pharma, improving the customer experience across stakeholders — including patients, caregivers, healthcare providers (HCP) and payers — can benefit both the healthcare ecosystem and the business outcome.
Innovators that do this well test new approaches and audiences while consistently creating quality experiences that help enable true engagement. This level of consumer “obsession” is essential to retaining customers and driving growth for pharma companies in the future.
So, how can you design solutions that yield meaningful customer impact and brand results? Standing out requires focus on delivering easy, purposeful, personalized and adaptable interactions at every touchpoint:
Consumers, patients, caregivers and healthcare providers should be able to easily navigate interactions with pharma companies to meet their needs. This is becoming increasingly important — our loyalty survey data shows that more than half (51%) of consumers say they are less likely to be loyal to a brand if its online experience isn't as easy or enjoyable as in person. That percentage is highest for Millennials (57%) and Generation Z (69%).
As interactions move from being in person to remote to fully digitally immersive, engagement will come from the ability to create unique human experiences in a digital environment. Our research has found that connections are based on the seamlessness of engagement across channels and the belief that the company has a shared purpose. We call this customer attraction.
Companies that communicate with purpose and creativity define their audiences by both behavioral and attitudinal segments and often enjoy higher levels of customer satisfaction. Pharma companies, whose mission is centered on improving patients’ lives, should seek out solutions that consider the whole of the person and are relevant for their customers, patients and communities.
Advanced analytics and artificial intelligence (AI) are giving many pharma companies new capabilities to automatically recommend the most effective channel to reach their target audience with relevant content. This new wealth of data is the result of generational shifts in comfort with providing personal information. That information can help create meaningful customer journeys and personas.
Starting with a robust internal data strategy and management processes, companies may also buy or build additional technology capabilities to drive personalization (such as customer data platforms and next best action engines). To improve returns, these tools should be integrated with existing technology infrastructure and processes should be evaluated, taking into account the implications for sales and marketing teams.
Success in the future will depend on pharma’s ability and agility to harness technology to meet an evolving set of stakeholder needs at a faster pace and on a broader scale. One step is to embed a test-and-learn capability within your commercial function to harness innovations in digital engagement, AI and machine learning to improve processes, time to market and content across your ecosystem of channels and collaborators.
As we look to the future, digital innovations will provide new arenas for engagement and new opportunities to support providers in their interactions with patients. The fully immersive digital experiences made possible with AI in the future could have the potential to take telehealth to another level. Participants will have a far greater sense of “being there” for conferences as well as in interactions with sales teams, medical professionals and patient support services. Companies that position themselves to capture this opportunity can gain competitive advantage.
The need to move toward a human+digital future is clear, but the challenge is how to leapfrog competitors through smart investments of time and innovation resources. A coordinated approach across the enterprise is recommended to drive impactful change. In a PwC Pulse Survey in 2022, 60% of executives said that digital transformation was their company’s most critical growth driver.
Ask yourself the following questions to gauge your readiness for customer engagement and take the recommended actions in the areas in which you can improve:
Pharma can move beyond buzzwords to behavior by defining and aligning the organizational rationale, goals and key performance indicators (KPIs) for enhancing customer experience. We find it helpful to use objectives that the organization is driving toward, such as growth or shareholder value. This can direct innovation energy toward customer experience efforts that build on past efforts and are not siloed.
The increasingly integrated nature of healthcare and the move toward account teaming means the definition of customer is expanding to care-adjacent stakeholders such as foundations, patient advocates and even payers. Creating holistic experiences requires new types of information sharing across commercial, medical, market access and R&D teams. Pharma companies should aim for consistency at each stage of the patient’s journey, including the movement from clinical trial to commercialization.
Pharma companies have identified areas customers find lacking today: clarity, connectedness, speed and personalization. Moving forward, industry leaders can differentiate themselves by investing in critical and complementary technical capabilities such as immersive and data-driven customer engagement, digitally enabled products, and innovative real-world evidence (RWE). We continue to see a large volume of digital experimentation, indicating that companies have not found the sweet spot between where to play, how to engage, and how to create patient impact and value.
Understanding the impact on people is critical for any transformation. To make adoption stick, organizations embarking on change should make it personal to every role, show the bigger picture and use real-time data and feedback to iterate. This approach enables employee buy-in to support and help drive the change throughout the organization.
References
1 Hims Inc. - Investor relations, accessed January 3, 2023.
2 “Hims & Hers launches new line of mental wellness supplements, with more options to help support stress, sleep and lack of focus,” Investorsforhims.com (February 7, 2022), accessed January 3, 2023.
3 Heather Landi. “Amazon scoops up primary care company One Medical in deal valued at $3.9B,” Fiercehealthcare.com (July 21, 2022), accessed January 3, 2023.
4 “Pfizer launches novel programs to put important support services at the fingertips of cancer patients,” Pfizer.com (October 5, 2017), accessed January 3, 2023.
5 Kite Konnect, Kiteconnect.com, accessed January 3, 2023.
6 “UnitedHealthcare introduces the use of predictive analytics to expand its capabilities to address social determinants of health,” Unitedhealthgroup.com, accessed January 3, 2023.
7 Rana Masud. “Novo Nordisk wins over doctors with AI email subject lines — and a human touch,” ECHEMI.com, accessed January 3, 2023.
8 Beth Snyder Bulik. “Biohaven accelerates DTC campaign timing for migraine med Nurtec,” Fiercepharma.com (April 20, 2020), accessed January 3, 2023.
9 “How Biohaven’s Nurtec ODT became a first-of-its-kind launch to cure the common migraine,” Marketingtwitter.com, accessed January 3, 2023.